Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURVALUNG_A durvalumab maintenance after chemoradiotherapy in frail limited-stage small cell lung cancer
2024-512224-11-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Apr 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in small cell lung cancer (SCLC), sponsored by Unicancer. Primary endpoint: Progression-free survival. Planned start Apr 2024; status: authorised.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-512224-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512224-11-00.